Fate Therapeutics
FATE
211 hedge funds and large institutions have $3.51B invested in Fate Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 89 increasing their positions, 64 reducing their positions, and 20 closing their positions.
45% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 20
39% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 64
19% more capital invested
Capital invested by funds: $2.95B → $3.51B (+$562M)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
4% more funds holding
Funds holding: 202 → 211 (+9)
1.36% less ownership
Funds ownership: 102.47% → 101.12% (-1.4%)
17% less call options, than puts
Call options by funds: $6.21M | Put options by funds: $7.44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$37.5M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$27.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.2M |
| 5 |
BlackRock
New York
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$23.9M |
| 2 |
Millennium Management
New York
|
-$23.6M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$21.3M |
| 4 |
Janus Henderson Group
London,
|
-$17.2M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$13.1M |
FATE Hedge Fund Activity: Q3 2020 in Review
211 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q3 2020, worth a combined $3.51B — up 19% from $2.95B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new FATE positions and 20 closed out — a net gain of 9 holders — while 89 added to existing stakes and 64 trimmed.
The largest buyer was Vanguard Group, adding an estimated $41.1M. The largest seller was Citadel Advisors, cutting an estimated $23.9M.
- 211 institutional investors held Fate Therapeutics (FATE) as of Q3 2020, up from 202 in Q2 2020.
- Funds reported $3.51B of Fate Therapeutics stock for Q3 2020, up 19% quarter-over-quarter.
- 29 funds opened new Fate Therapeutics positions in Q3 2020 and 20 closed out, a net change of +9 holders.
- The largest Fate Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $41.1M added.
- The largest Fate Therapeutics seller in Q3 2020 was Citadel Advisors, an estimated $23.9M sold.
Based on aggregated 13F filings for Q3 2020.